PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma

被引:8
|
作者
Garige, Mamatha [1 ]
Ghosh, Susmita [1 ]
Norris, Alexis [2 ]
Li, Guangyuan [1 ]
Poncet, Sarah [1 ]
Chou, Chao-Kai [3 ]
Wu, Wells W. [3 ]
Shen, Rong-Fong [3 ]
Sourbier, Carole [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Biotechnol Review & Res 1, Off Biotechnol Prod,Off Pharmaceut Qual, Silver Spring, MD 20993 USA
[2] US FDA, Ctr Vet Med, Div Anim Bioengn & Cellular Therapies, Off New Anim Drug Evaluat, Rockville, MD USA
[3] US FDA, Ctr Biol Evaluat & Res, Facil Biotechnol Resources, Drug Adm, Silver Spring, MD USA
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
PD-L1 (B7-H1; CD274); clear cell renal cell carcinoma (ccRCC); interferon gamma; metabolism; tryptophan; kynurenine; glycolysis; INDOLEAMINE 2,3-DIOXYGENASE; SUPPRESSOR-CELLS; INTERFERON-GAMMA; T-CELLS; CANCER; MICROENVIRONMENT; INFLAMMATION; EXPRESSION; LINDAU; ACID;
D O I
10.3389/fonc.2022.858379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immune checkpoint programmed death-ligand 1 (PD-L1) is expressed on the cell surface of tumor cells and is key for maintaining an immunosuppressive microenvironment through its interaction with the programmed death 1 (PD-1). Clear cell renal cell carcinoma (ccRCC) is a highly immunogenic cancer characterized by an aberrant aerobic glycolytic metabolism and is known to overexpress PD-L1. Multiple immunotherapies have been approved for the treatment of ccRCC, including cytokines and immune checkpoint inhibitors. Recently the intrinsic role of PD-L1 and interferon gamma (IFN gamma) signaling have been studied in several types of tumor cells, yet it remains unclear how they affect the metabolism and signaling pathways of ccRCC. Using metabolomics, metabolic assays and RNAseq, we showed that IFN gamma enhanced aerobic glycolysis and tryptophan metabolism in ccRCC cells in vitro and induced the transcriptional expression of signaling pathways related to inflammation, cell proliferation and cellular energetics. These metabolic and transcriptional effects were partially reversed following transient PD-L1 silencing. Aerobic glycolysis, as well as signaling pathways related to inflammation, were not induced by IFN gamma when PD-L1 was silenced, however, tryptophan metabolism and activation of Jak2 and STAT1 were maintained. Our data demonstrate that PD-L1 expression is required to mediate some of IFN gamma's effect in ccRCC cells and highlight the importance of PD-L1 signaling in regulating the metabolism of ccRCC cells in response to inflammatory signals.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Implications of Correlation Between PBRM1 and PD-L1 Expression in Renal Cell Carcinoma, Clear Cell Type
    Lee, Jieun
    Choe, Gheeyoung
    Lee, Kyu Sang
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 617 - 617
  • [32] Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma
    Sorokina, Maria
    Stupichev, Danil
    Lyu, Yang
    Ramachandran, Akshaya
    Miheecheva, Natalia
    Brown, Jessica H.
    Nomie, Krystle
    Postovalova, Ekaterina
    Bagaev, Alexander
    Tsiper, Maria
    Hsieh, James J.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : E374 - E381
  • [33] PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
    Fay, Andre Poisl
    Callea, Marcella
    Gray, Kathryn P.
    Ho, Thai Huu
    Song, Jiaxi
    Carvo, Ingrid
    Lampron, Megan E.
    Albiges, Laurence
    Stanton, Melissa L.
    McDermott, David F.
    Atkins, Michael B.
    Freeman, Gordon James
    Hirsch, Michelle S.
    Signoretti, Sabina
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
    Abbas, M.
    Steffens, S.
    Bellut, M.
    Eggers, H.
    Grosshennig, A.
    Becker, J. U.
    Wegener, G.
    Schrader, A. J.
    Gruenwald, V.
    Ivanyi, P.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [35] Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
    M. Abbas
    S. Steffens
    M. Bellut
    H. Eggers
    A. Großhennig
    J. U. Becker
    G. Wegener
    A. J. Schrader
    V. Grünwald
    P. Ivanyi
    Medical Oncology, 2016, 33
  • [36] PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases
    Callea, Marcella
    Genega, Elizabeth M.
    Gupta, Mamta
    Fay, Andre P.
    Song, Jiaxi
    Carvo, Ingrid
    Bhatt, Rupal Satish
    McDermott, David F.
    Atkins, Michael B.
    Choueiri, Toni K.
    Freeman, Gordon J.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [37] TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1
    Li, Jinxin
    Sun, Huimin
    Fu, Meiling
    Zheng, Zeyuan
    Xu, Chunlan
    Yang, Kunao
    Liu, Yankuo
    Xuan, Zuodong
    Bai, Yang
    Zheng, Jianzhong
    Zhao, Yue
    Shi, Zhiyuan
    Shao, Chen
    ISCIENCE, 2023, 26 (07)
  • [38] Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
    Bialek, Joanna
    Yankulov, Stefan
    Kawan, Felix
    Fornara, Paolo
    Theil, Gerit
    BIOMEDICINES, 2022, 10 (12)
  • [39] Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
    Denize, Thomas
    Hou, Yue
    Pignon, Jean-Christophe
    Walton, Emily
    West, Destiny J.
    Freeman, Gordon J.
    Braun, David A.
    Wu, Catherine J.
    Gupta, Saurabh
    Motzer, Robert J.
    Atkins, Michael B.
    McDermott, David
    Choueiri, Toni K.
    Shukla, Sachet A.
    Signoretti, Sabina
    CLINICAL CANCER RESEARCH, 2022, 28 (18) : 4045 - 4055
  • [40] Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
    Kammerer-Jacquet, Solene-Florence
    Deleuze, Antoine
    Saout, Judikael
    Mathieu, Romain
    Laguerre, Brigitte
    Verhoest, Gregory
    Dugay, Frederic
    Belaud-Rotureau, Marc-Antoine
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)